Abstract: Techniques for improving user experience with connected televisions are described. A computing system (e.g., server) can transmit a video content associated with a product to a connected television (CTV). The video content can include a code (e.g., QR code) that is scannable. Additionally, the system can receive, from a user device of a user, an indication that the user has scanned the code. Moreover, the system can determine, using a mapping database, that the user device is associated with the CTV. For example, the mapping database can indicate that the user is associated with the CTV and the user device. Furthermore, in response to determining that the user device is associated with the CTV, the system can transmit instructions to modify the video content to the CTV.

Abstract: The present disclosure provides techniques for presenting a reward impression. A computing system can receive, from a client device, a request to view the reward impression having a first time slot and a second time slot. The computing system can calculate a first conversion rate associated with a first content item being presented in the first time slot and a second conversion rate associated with a second content item being presented in the second time slot. The computing system can select, using the one or more machine-learned models based on the first conversion rate and the second conversion rate, the first content item and the second content item from a plurality of content items. The computing system can cause the presentation of the first content item in the first time slot and the second content item in the second time slot of the reward impression.

Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.

Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemic-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.

Abstract: Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.

Abstract: The present invention is directed to an apparatus for throwing and catching a football by a user of the apparatus. The apparatus includes a football having a connector, such as a loop, attached to one end of the football, specifically the point of the football; an elastic cord having connectors at opposite ends, with one connector configured to attach to the connector on the football and the opposite connector configured to attach to a stationary object or anchor to anchor the apparatus during use, and wherein each connector attached to the elastic cord is configured to swivel such that the opposite ends of each connector can freely rotate relative to each other to allow the football to rotate relative to the elastic cord and to allow the elastic cord to rotate relative to the anchor.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for locating, using a content binder library, content elements of a publisher page. For each content element, the library determines presentation attributes of the content element and at least one other library detects a mode parameter that specifies a type of user device that is requesting the publisher page. The library selects a particular content element from the publisher page as a reference point for positioning a digital component at the publisher page using the presentation attributes of the particular content element. The library determines a location of the publisher page for rendering the digital component, where the location is determined based on the reference point and the mode parameter. The library provides the digital component for display at the location of the publisher page.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for locating, using a content binder library, content elements of a publisher page. For each content element, the library determines presentation attributes of the content element and at least one other library detects a mode parameter that specifies a type of user device that is requesting the publisher page. The library selects a particular content element from the publisher page as a reference point for positioning a digital component at the publisher page using the presentation attributes of the particular content element. The library determines a location of the publisher page for rendering the digital component, where the location is determined based on the reference point and the mode parameter. The library provides the digital component for display at the location of the publisher page.

Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for locating, using a content binder library, content elements of a publisher page. For each content element, the library determines presentation attributes of the content element and at least one other library detects a mode parameter that specifies a type of user device that is requesting the publisher page. The library selects a particular content element from the publisher page as a reference point for positioning a digital component at the publisher page using the presentation attributes of the particular content element. The library determines a location of the publisher page for rendering the digital component, where the location is determined based on the reference point and the mode parameter. The library provides the digital component for display at the location of the publisher page.

Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance.

Abstract: Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.

Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemic-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for locating, using a content binder library, content elements of a publisher page. For each content element, the library determines presentation attributes of the content element and at least one other library detects a mode parameter that specifies a type of user device that is requesting the publisher page. The library selects a particular content element from the publisher page as a reference point for positioning a digital component at the publisher page using the presentation attributes of the particular content element. The library determines a location of the publisher page for rendering the digital component, where the location is determined based on the reference point and the mode parameter. The library provides the digital component for display at the location of the publisher page.

Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.

Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance.

Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance.

Abstract: An incontinence garment for wear by a user is provided. The user has an anatomy. The incontinence garment comprises a protective undergarment having a waist opening and a pair of leg openings. An opening is formed in the protective undergarment approximately centered between the leg openings for accommodating the wearers anatomy. An outer garment is positionable over the protective undergarment with the outer garment having a waist opening and a pair leg openings and the outer garment being free from any other openings. The combined protective undergarment and outer garment offers a dual layer of absorbent protection.

Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.